In multiple sclerosis (MS), which is an autoimmune disease of the central nervous system (CNS) caused by autoreactive T cells recognizing myelin epitope, resulting in irreversible disability in more than 1 million people in the United States, CD4 + T cells modified with CAR targeting myelin oligodendrocyte glycoprotein (MOG) and murine FoxP3 gene have shown successful results in controlling a murine model of MS [64]. The gene discussed is CD4; the disease is myeloid sarcoma.